TN HB1216 | 2017-2018 | 110th General Assembly
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on February 9 2017 - 25% progression, died in chamber
Action: 2017-02-15 - Assigned to s/c Health Subcommittee
Text: Latest bill text (Draft #1) [PDF]
Status: Introduced on February 9 2017 - 25% progression, died in chamber
Action: 2017-02-15 - Assigned to s/c Health Subcommittee
Text: Latest bill text (Draft #1) [PDF]
Summary
As introduced, requires the commissioner of health, in consultation with the commissioner of mental health and substance abuse services, to study and report to the health committee of the house of representatives and the health and welfare committee of the senate, on or before January 15, 2018, concerning any recommended changes to prescribing guidelines for buprenorphine products, or to Tennessee Code Annotated, Section 53-11-311. - Amends TCA Title 53, Chapter 11, Part 3.
Title
As introduced, requires the commissioner of health, in consultation with the commissioner of mental health and substance abuse services, to study and report to the health committee of the house of representatives and the health and welfare committee of the senate, on or before January 15, 2018, concerning any recommended changes to prescribing guidelines for buprenorphine products, or to Tennessee Code Annotated, Section 53-11-311. - Amends TCA Title 53, Chapter 11, Part 3.
Sponsors
| Rep. Gary Hicks [R] |
History
| Date | Chamber | Action |
|---|---|---|
| 2017-02-15 | House | Assigned to s/c Health Subcommittee |
| 2017-02-15 | House | P2C, ref. to Health Committee |
| 2017-02-13 | House | P1C. |
| 2017-02-09 | House | Intro. |
| 2017-02-09 | House | Filed for intro. |
Same As/Similar To
SB1323 (Crossfiled) 2017-02-13 - Passed on Second Consideration, refer to Senate Health and Welfare Committee
